A Contemporary Look at Classic Trials in Atrial Fibrillation: What Do They Really Show and How Might They Apply to Future Therapies?

American Journal of Cardiology

Volumn 102, Issue 6 SUPPL., 2008, Pages 3H-11H

  Reiffel, James A ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; ENCAINIDE; FLECAINIDE; PLACEBO; PROPAFENONE; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; VERAPAMIL;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN DISEASE; BRAIN HEMORRHAGE; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; EXERCISE TOLERANCE; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMODYNAMICS; HOSPITALIZATION; HUMAN; METHODOLOGY; MORBIDITY; MORTALITY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RESUSCITATION; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SINUS RHYTHM; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 51749117117     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.06.024     Document Type: Article

References (32)

1. AFFIRM Investigators. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 149 (2005) 112-120
2. Singh S.N., Tang X.C., Singh B.N., Dorian P., Reda D.J., Harris C.L., Fletcher R.D., Sharma S.C., Atwood J.E., Jacobson A.K., et al., SAFE-T Investigators. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation. J Am Coll Cardiol 48 (2006) 721-730
3. Naccarelli G.V. Atrial fibrillation: impact of recent clinical advances. http://www.medscape.com/viewprogram/323_pnt Accessed August 20, 2007
4. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
5. Van Gelder I.C., Hagens V.E., Bosker H.A., Kingma J.H., Kamp O., Kingma T., Said S.A., Darmanata J.I., Timmermans A.J.M., Tijssen J.G.P., Crijns H.J.G.M., and Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002) 1834-1840
6. Crijns H.J.G.M. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. Drugs 65 (2005) 1651-1667
7. Hohnloser S.H., Kuck K.-H., Lilienthal J., and PIAF Investigators. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomized trial. Lancet 356 (2000) 1789-1794
8. Carlsson J., Miketic S., Windeler J., Cuneo A., Haun S., Micus S., Walter S., Tebbe U., and STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41 (2003) 1690-1696
9. Opolski G., Torbicki A., Kosior D.A., Szulc M., Wozakowska-Kaplon B., Kolodziej P., Achemczyk P., and Investigators of the Polish HOT CAFÉ trial. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFÉ) study. Chest 126 (2004) 476-486
10. The Planning and Steering Committees of the AFFIRM study for the National Heart, Lung and Blood Institute AFFIRM Investigators. Atrial fibrillation follow-up investigation of rhythm management-the AFFIRM study design. Am J Cardiol 79 (1997) 1198-1202
11. Hagens V.E., Crijns H.J.G.M., Van Veldhuisen D.J., Van Den Berg M.P., Rienstra M., Ranchor A.V., Bosker H.A., Kamp O., Tijssen J.G.P., Veeger N.J.G.M., Van Gelder I.C., and Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical Cardioversion (RACE) study. Am Heart J 149 (2005) 1106-1111
12. Pedersen O.D., Bagger H., Keller N., Marchant B., Køber L., Torp-Pedersen C., and Danish Investigations of Arrhythmia and Mortality ON Dofetilide Study Group. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation 104 (2001) 292-296
13. AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109 (2004) 1509-1513
14. Singh B.N., Singh S.N., Reda D.J., Tang X.C., Lopez B., Harris C.L., Fletcher R.D., Sharma S.C., Atwood J.E., Jacobson A.K., et al., SAFE-T Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352 (2005) 1861-1872
15. Thrall G., Lane D., Carroll D., and Lip G.Y.H. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 119 (2006) 448.e1-448.e19
16. Dorian P., Jung W., Newman D., Paquette M., Wood K., Ayers G.M., Camm J., Akhtar M., and Luderitz B. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 36 (2000) 1303-1309
17. Van Gelder I.C., Crijns H.J.G.M., Blanksma P.K., Landsman M.L.J., Posma J.L., Van Den Berg M.P., Meijler F.L., and Lie K.I. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 72 (1993) 560-566
18. Coplen S.E., Antman E.M., Berlin J.A., Hewitt P., and Chalmers T.C. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 82 (1990) 1106-1116
19. Flaker G.C., Blackshear J.L., McBride R., Kronmal R.A., Halperin J.L., Hart R.G., and Stroke Prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 20 (1992) 527-532
20. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., and Greene H.L. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
21. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 (1989) 406-412
22. Pritchett E.L., and Wilkinson W.E. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 67 (1991) 976-980
23. Teo K.K., Yusuf S., and Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 270 (1993) 1589-1595
24. Cairns J.A., Connolly S.J., Roberts R., Gent M., and Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 349 (1997) 675-682
25. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P., and European Myocardial Infarction Amiodarone Trial Investigators. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 349 (1997) 667-674
26. Julian D.G., Jackson F.S., Szekely P., and Prescott R.J. A controlled trial of sotalol for 1 year after myocardial infarction. Circulation 67 (1983) 161-162
27. Camm A.J., Pratt C.M., Schwartz P.J., Al-Khalidi H.R., Spyt M.J., Holroyde M.J., Karam R., Sonnenblick E.H., Brum J.M.G., and Azimilide Post-Infarct Survival Evaluation (ALIVE) Investigators. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 109 (2004) 990-996
28. Singh S.N., Fletcher R.D., Fisher S.G., Singh B.N., Lewis H.D., Deedwania P.C., Massie B.M., Colling C., and Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 333 (1995) 77-82
29. Doval H.C., Nul D.R., Grancelli H.O., Perrone S.V., Bortman G.R., Curiel R., and Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 344 (1994) 493-498
30. Steinberg J.S., Sadaniantz A., Kron J., Krahn A., Denny D.M., Daubert J., Campbell W.B., Havranek E., Murray K., Olshansky B., and AFFIRM Investigators. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 109 (2004) 1973-1980
31. Reiffel J.A., and Naccarelli G.V. Antiarrhythmic drug therapy for atrial fibrillation: are the guidelines guiding clinical practice?. Clin Cardiol 29 (2006) 97-102
32. Fuster V., Rydén L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Le Heuzey J.-Y., Kay G.N., Lowe J.E., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation-Executive Summary. Circulation 114 (2006) 700-752